Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Receptos Inc.

Division of Celgene Corp.
receptos.com

Latest From Receptos Inc.

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Celgene Plots Blockbuster Course For Ozanimod

Celgene, in need of good news, posted positive data on a potential blockbuster for multiple sclerosis at the joint ECTRIMS-ACTRIMS meeting. Ozanimod could have important safety and tolerability advantages over Gilenya, but investors already were expecting good news.

Clinical Trials Research & Development

Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization

A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.

Research & Development Neurology

Safety Is Key As Celgene's Ozanimod Succeeds In First Pivotal MS Test

Celgene's ozanimod successfully cleared its first Phase III hurdle in multiple sclerosis, but safety will be the S1P receptor modulator's differentiating factor in results presented later this year, with additional value coming from ulcerative colitis and Crohn's disease in the coming years.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Receptor Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celgene Corp.
  • Senior Management
  • Faheem Hasnain, Pres. & CEO
    Graham Cooper, CFO
    Chrysa Mineo, SVP, Corp. Dev.
    Shelia Gujrathi, MD, CMO
    Robert J Peach, PhD, CSO
    Marcus T Boehm, PhD, CTO
  • Contact Info
  • Receptos Inc.
    Phone: (858) 652-5700
    3033 Science Park Rd.
    Ste. 300
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register